AIM ImmunoTech Inc. (AIM) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-16

Key Insights

The reporting person, David I. Chemerow, is a director of AIM ImmunoTech Inc. and acquired 25,000 shares of the company's common stock through the conversion of 25 shares of Series G Convertible Preferred Stock.
The transaction was executed on March 12, 2026, and Chemerow now beneficially owns a total of 28,441 shares of the company's common stock.
The conversion of preferred shares into common stock at a rate of 1,000 shares per preferred share suggests the company is providing director compensation in the form of equity.

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-16

The CEO and President, Thomas K. Equels, acquired 25,000 shares of common stock through the conversion of 25 shares of Series G Convertible Preferred Stock, indicating his confidence in the company's future.
The exercise price for the conversion of the preferred shares to common shares was $0, effectively allowing Equels to acquire the shares at a significant discount.
Equels now holds a direct ownership of 63,922 shares of common stock, suggesting his alignment with shareholders and long-term commitment to the company.

Filed: 2026-02-06

David Chemerow, a director of AIM ImmunoTech Inc., acquired 2,800 shares of the company's common stock at $1.23 per share, indicating insider buying activity.
The acquisition increased Chemerow's beneficial ownership in the company, with a total of 3,441 shares now held indirectly through The David I Chemerow 1992 Trust.
Insider buying can signal management's confidence in the company's prospects and may be a positive indicator for investors.

Other reports for AIM ImmunoTech Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.